ARTH - Arch Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3289
+0.0389 (+13.41%)
As of 10:25AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2900
Open0.2800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2800 - 0.3289
52 Week Range0.2600 - 0.6900
Volume16,800
Avg. Volume372,875
Market Cap56.756M
Beta (3Y Monthly)-1.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Trade prices are not sourced from all markets
  • GlobeNewswire27 days ago

    Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational

    FRAMINGHAM, Mass., May 30, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswirelast month

    Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering

    Arch Therapeutics, Inc. (ARTH)(“Arch” or the “Company”), a developer of novel liquid, gel and solid hemostatic and wound care devices, today announced the pricing of registered direct offering of approximately 8.6 million units, each unit consisting of a share of the Company’s common stock, and a Series H Warrant (“Series H Warrant”) to purchase 1 (one) share of our common stock for the combined purchase price of $0.325 per unit. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions.

  • GlobeNewswire2 months ago

    Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video

    FRAMINGHAM, Mass., April 24, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of products for dermal science and biosurgical applications,.

  • GlobeNewswire4 months ago

    Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference

    FRAMINGHAM, Mass., March 11, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care.

  • GlobeNewswire5 months ago

    Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference

    FRAMINGHAM, Mass., Feb. 05, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswire6 months ago

    Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019

    FRAMINGHAM, Mass., Dec. 20, 2018 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswire6 months ago

    Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the 510(k) premarket notification for AC5™ Topical Gel has been reviewed and cleared by the U.S. Food and Drug Administration (FDA), allowing for the product to be marketed. AC5 Topical Gel is a topical dressing indicated for use in the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. Marketing clearance, which requires the provision of necessary documentation and data to the FDA, is an essential milestone to the path to commercialization.

  • GlobeNewswire7 months ago

    Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, presented an update on its corporate milestones, plans and timetables at the LD Micro Main Event XI in Los Angeles, California. Chief Executive Officer, Terrence W. Norchi, MD provided the following summary.

  • GlobeNewswire7 months ago

    Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court

    FRAMINGHAM, Mass., Dec. 04, 2018 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswire7 months ago

    Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe

    Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company has submitted the required documents for AC5™ Topical Hemostat (AC5)1 to its Notified Body as it seeks a CE mark, which is a next step on the path to commercialization in countries governed by the European Medical Devices Directive (MDD). This first such submission by Arch to a European regulatory body follows the recent submission of a 510(k) premarket notification to the US Food and Drug Administration. Receipt of a CE mark would allow AC5 to be commercialized for use on external wounds, and in particular, for controlling bleeding by mechanically sealing areas of leakage and managing wounds in skin.

  • GlobeNewswire7 months ago

    Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the LD Micro Main Event XI. Chief Executive Officer, Terrence W. Norchi, MD will deliver a corporate presentation on Tuesday, December 4 at 12:00 PM Pacific Time in Track 1.